Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia

Figures & data

Table 1 Primary Outcome of Ejection Fraction (EF) Before and After Receiving Sacubitril / Valsartan (Sac/Val)

Case	Age	Baseline EF Prior Chemotherapy	Type of Cancer	Type of Chemotherapy	EF Prior Sac/Val Use	EF After Sac/Val Use	Time of EF Reading After the Sac/Val Use (Month)	Change in EF (%)	First Dose (mg)	Last Dose (mg)
A	54-year-old female	55%	Metastatic high-grade uterine leiomyosarcoma	Doxorubicin	20–25%	45%	12	80	97/103 BID	49/51 BID
B	70-year-old male	45%	Stage IV non-Hodgkin lymphoma	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) chemotherapy	20%	30%	12	50	24/26 BID	97/103 BID
C	62-year-old female	55%	Advanced colon cancer	Folinic acid, fluorouracil, and irinotecan (FOLFIRI) and panitumumab	10–15%	15–25%	15	50	24/26 BID	24/26 BID
D	66-year-old female	50%	Advanced breast cancer	AC (doxorubicin, cyclophosphamide)	25%	35%	12	40	24/26 BID	97/103 BID
E	67-year-old female	55%	Advanced breast cancer	Doxorubicin, Cyclophosphamide (AC) were followed by four cycles of docetaxel, Pertuzumab, and trastuzumab	25%	27%	12	8	24/26 BID	24/26 BID
F	45-year-old female	50–55%	Advanced breast cancer	Doxorubicin, Cyclophosphamide (AC)	20%	51%	7	155	97/103 BID	97/103 BID
G	62-year-old male	30%	Rectal cancer	5- fluorouracil	30%	30%	7	0	24/26 BID	97/103 BID
H	67-year-old male	30%	Diffuse large B-cell lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab Vincristine (R-CEOP) chemotherapy	20–25%	20–25%	17	0	49/51 OD	49/51 OD

Abbreviations: BID, twice a day; OD, once a day.

Data Sharing Statement

Upon reasonable request, the corresponding author is willing to provide the data.